

Table 15.7
Immunosuppression Use for Maintenance by Regimen
Two Years Following Transplantation, 1998 to 2006
Recipients with Kidney Transplants

	Transplant Year								
	1998	1999	2000	2001	2002	2003	2004	2005	2006
Transplants	12,452	12,761	13,617	14,271	14,779	15,137	16,004	16,483	17,093
Functioning Graft at 2 Years PostTx	9,974	10,223	11,061	11,835	12,311	12,634	13,389	13,776	14,533
With Maintenance Use Recorded at 2 Years PostTx	9,419	9,704	10,830	11,527	11,993	12,345	13,042	11,105	10,766
CyA	0.3%	0.7%	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%	0.2%
Tac	0.8%	0.8%	0.8%	1.5%	1.8%	1.9%	2.3%	3.1%	3.1%
--- + MMF/MPA	0.1%	0.1%	0.1%	0.1%	0.1%	0.3%	0.3%	0.3%	0.2%
CyA + MMF/MPA	1.3%	1.1%	1.4%	1.5%	1.7%	2.3%	2.3%	2.1%	1.6%
Tac + MMF/MPA	1.8%	2.2%	2.9%	4.4%	6.5%	9.9%	15.5%	22.1%	25.9%
--- + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + OtherAntimet	0.4%	0.2%	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.0%
Tac + OtherAntimet	0.3%	0.2%	0.2%	0.2%	0.3%	0.2%	0.3%	0.4%	0.6%
--- + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Tac + MMF/MPA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
--- + Siro/Evero	0.0%	0.0%	0.2%	0.3%	0.2%	0.1%	0.2%	0.2%	0.2%
CyA + Siro/Evero	0.6%	0.2%	0.3%	0.4%	0.8%	0.8%	0.8%	1.0%	0.8%
Tac + Siro/Evero	0.0%	0.1%	0.9%	2.1%	2.4%	2.7%	2.1%	1.6%	1.0%
--- + MMF/MPA + Siro/Evero	0.0%	0.0%	0.2%	0.5%	0.7%	1.4%	1.9%	2.4%	2.5%
CyA + MMF/MPA + Siro/Evero	0.0%	0.0%	0.1%	0.1%	0.0%	0.1%	0.0%	0.0%	0.0%
Tac + MMF/MPA + Siro/Evero	0.0%	0.1%	0.2%	0.3%	0.5%	0.8%	0.7%	0.8%	0.6%
--- + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Tac + OtherAntimet + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
--- + Steroids	0.6%	0.7%	0.3%	0.5%	0.4%	0.5%	0.3%	0.2%	0.2%
CyA + Steroids	8.0%	6.9%	4.1%	2.4%	1.5%	1.4%	0.9%	0.7%	0.5%
Tac + Steroids	6.5%	7.2%	7.4%	6.5%	6.1%	5.1%	4.5%	4.4%	4.7%
--- + MMF/MPA + Steroids	1.6%	2.0%	1.4%	1.3%	1.3%	1.1%	1.2%	1.1%	0.9%
CyA + MMF/MPA + Steroids	39.7%	36.3%	31.0%	22.8%	18.5%	14.0%	12.1%	7.4%	5.1%
Tac + MMF/MPA + Steroids	23.2%	27.4%	29.7%	35.0%	38.6%	41.3%	40.0%	40.4%	41.1%
--- + OtherAntimet + Steroids	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
CyA + OtherAntimet + Steroids	6.6%	4.6%	2.9%	1.5%	0.7%	0.5%	0.3%	0.2%	0.1%
Tac + OtherAntimet + Steroids	2.6%	2.1%	2.0%	2.0%	1.6%	1.4%	1.3%	1.3%	1.6%
--- + Siro/Evero + Steroids	0.2%	0.5%	0.7%	1.0%	0.7%	0.9%	0.9%	0.8%	0.5%
CyA + Siro/Evero + Steroids	2.3%	2.3%	3.7%	2.9%	2.5%	1.9%	1.4%	1.1%	1.0%
Tac + Siro/Evero + Steroids	0.5%	1.3%	4.8%	6.5%	5.6%	4.4%	3.2%	2.3%	1.8%
Other Regimen	2.3%	3.0%	4.2%	5.8%	6.9%	6.7%	7.1%	5.7%	5.3%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Percentages are calculated based on the total number of patients with maintenance use at two years following transplantation. They sum to 100 percent for each column. Transplants prior to year 1998 are not reported due to insufficient reporting of immunosuppressive drug use.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.